SUMMARY. The investigation of the interaction between angiotensin II and its receptors in human subjects has been hampered by the inaccessibility of human tissue containing angiotensin II receptors. In order to find a more accessible angiotensin II-binding tissue, we studied angiotensin II binding to platelets in normal human volunteers. Platelet preparations purified on Ficoll: Isopaque gradients were incubated with 125
SUMMARY. The investigation of the interaction between angiotensin II and its receptors in human subjects has been hampered by the inaccessibility of human tissue containing angiotensin II receptors. In order to find a more accessible angiotensin II-binding tissue, we studied angiotensin II binding to platelets in normal human volunteers. Platelet preparations purified on Ficoll: Isopaque gradients were incubated with 125 I-angiotensin II (30 PM), with and without unlabeled angiotensin at 22°C, separating bound from free hormone by microcentrifugation. Binding was linearly related to the number of platelets incubated, and, at 8 X 10 5 cells//il, specific binding ranged from 0.8 to 10%. ] angiotensin II > angiotensin I. The effect of high and low sodium (Na) intake (200 vs. 10 mEq/day) on platelet angiotensin II binding was studied in nine subjects. Compared to low Na, high Na intake produced an 80% increase in the angiotensin II-binding capacity (P < 0.01) with no significant change in binding affinity. We conclude that human platelets possess angiotensin receptors whose binding characteristics and modulation by dietary sodium resemble the properties of the receptors on "classical" animal angiotensin target tissues. The platelet may provide an accessible source of angiotensin receptors for a detailed study of angiotensin-receptor interaction in human tissue. ANIMAL studies have shown that the effect of angiotensin II on target tissues is mediated by the interaction between the homone and receptor sites on the cell surface . Direct studies of these receptors suggest that some changes in tissue responsiveness to angiotensin (such as occur with changes in dietary electrolyte intake) are mediated by changes at the receptor level Douglas, 1980; Gunther et al., 1980a) . Unfortunately, no similar direct receptor studies have been performed in man, due to the inaccessibility of classical angiotensin target tissues (e.g., adrenal, vascular smooth muscle) in human subjects. However, circulating blood cells have been shown to possess receptor sites for several other hormones, such as insulin and catecholamines (Gavin et al., 1973; Alexander et al., 1978) . The demonstration of these blood cell receptors not only permitted detailed studies of ligand-receptor interaction in human tissue, but also lead to the recognition of functions for these hormones in tissues where previously none were suspected. Therefore, we examined the possibility that human blood cells could possess angiotensin II receptors. Our studies have demonstrated angiotensin receptors on platelets which, similar to animal target tissues, are regulated by dietary sodium intake.
Methods

Materials
12S
I-Angiotensin II (1500-1800 /iCi/g) was obtained from New England Nuclear. This material was resuspended in sterile, distilled water and frozen in 20-fi\ aliquots in the dark at -10°C until used (always within 30 days of resuspension). Under these conditions, this material is stable as assessed by reverse-phase high performance liquid chromatography [micro-Bondapack C-18 column (Waters Associates); 18% acetonitrile in 0. ; and bovine serum albumin (Miles Lab).
Platelet Preparation
The subjects for these studies were normal volunteers taking no medications. The protocol was approved by the Human Subjects Committee of our hospital. Platelets were prepared from whole blood anticoagulated with EDTA or heparin. Fifty to 60 ml of blood provided enough platelets for a complete competition curve (see below). Buffy coats were diluted 1:4 with medium-199-containing EDTA (5 ITIM) and then centrifuged through a Ficoll:Isopaque solution (specific gravity 1.077) for 20 minutes at 200 g. The mononuclear/platelet layers then were aspirated and washed twice with normal saline. After the second wash, the suspensions were centrifuged for 5 minutes at 100 g, pelleting the mononuclear cells but leaving the platelets in suspension. Prepared this way, the platelets contained less than 2% red and white cell contamination. The platelets then were collected at 1000 g for 10 minutes and resuspended in medium-199 containing 3.6 mEq/liter potassium, 0.5% bo-vine serum albumin, and 5 mM EDTA and DFP. The resultant suspensions then were used in the binding assays. Platelets were counted manually by standard techniques. These manual counts correlated well (±5%) with automated counts (Coulter counter).
Binding Assay
The techniques used for binding studies were modifications of those described by Lin and Goodfriend (1970) and Gambhir et al. (1978) ]. The platelet pellet then was cut off and counted as "bound" hormone; the supernate was counted as free in a Packard gamma counter (Packard Instrument Co., Inc.). The nonspecific binding was defined as the amount of angiotensin bound to platelets in the presence of excess (10~6 M) unlabeled angiotensin II. In studies with tracer amounts (30 pM) of 125 I-angiotensin II, nonspecific binding amounted to less than 1% of added label and ranged from 10 to 30% of total binding. In studies with varying concentrations of labeled angiotensin II, nonspecific binding represented a constant fraction of the total hormone concentration in the incubation.
Red and White Cell Binding
Because the platelet suspensions contained small amounts of red cell and mononuclear leukocyte contamination, we assessed binding to purified red and white cells in six subjects (all sodium restricted) to assure that the observed binding was to platelets and not to those contaminating cells. For these studies, platelet suspensions were prepared in the usual fashion and red and white cell contamination was calculated by cell counts. Purified red cells then were obtained from the cell pellets of EDTA-anticoagulated whole blood of the same subjects and were washed twice with 0.9% NaCl before binding assay. Mononuclear white cells (lymphocytes and monocytes) were obtained by ficolhlsopaque centrifugation and then were pelleted at 100 g for 5 minutes. The red and white cells were resuspended in medium-199, and the cell concentrations adjusted to match those of the contaminants in the platelet suspension. Thus, for each of these six subjects, there were three cell suspensions: platelets (including red and white cell contaminants), red cells, and mononuclear white cells. These suspensions were then incubated at 22°C for 90 minutes with 30 pM 125 I-angiotensin II with and without 10~6 M unlabeled angiotensin II to assess specific and non-specific binding.
Effect of Dietary Sodium
For these studies, nine normal subjects were studied as inpatients in the Clinical Research Center of the Brigham and Women's Hospital. They consumed constant diets containing 100 mEq potassium per day with either 10 or 200 mEq sodium. A 200 mEq sodium intake is equivalent to 12 g of NaCl [by comparison, the average American adult consumes 10 g/day (Dahl, 1977) ]. Each subject was studied on both sodium intakes, and the order of diets was randomized. When urinary electrolyte determinations indicated that metabolic balance had been achieved (usually after 4-5 days on the diets), blood was drawn for platelet collection, and binding assays were performed as outlined above.
Statistics
Results are presented as mean values ± SEM. Binding was analyzed by the method of Scatchard (1949) . Curvilinear Scatchard plots were analyzed with a computer-assisted curve-fitting program (MLAB) in the PROPHET computer system. In addition, the dissociation constant (KD) was estimated from displacement studies as the total ligand concentration required to inhibit 125 I-angiotensin II binding by 50% (IC50). Comparison of the relative potencies of unlabeled peptides are presented as dose ratios (i.e., IC50 angiotensin II/IC50 peptide). For group comparisons, we used the paired r-test or, for non-paired or non-parametric data, the Fisher exact test and the Wilcoxon signed rank tests. Linear regression was assessed with the least squares technique (Snedecor and Cochran, 1967) .
Results
Binding Characteristics
Using the outlined methodology, we found reproducible specific binding of labeled angiotensin to platelets. The intraassay coefficient of variation was 7.3%.
Time Course of Binding and Effect of Cell Number
In assessing the time course of binding, we incubated labeled hormone with platelets at 22°C and stopped the equilibration by centrifugation at varying time periods. Specific binding increased rapidly for 30 minutes, then more slowly between 30 and 60 minutes (Fig. 1 ). There was a constant plateau between 60 and 120 minutes where binding remained relatively constant. Non-specific binding achieved 90% of its maximal level within the first 5 minutes and remained constant throughout the full 120 minutes. At 37°C, specific binding increased more rapidly and, in paired experiments, achieved slightly greater levels compared to 22°C (3.4 ± .9 vs. 2.8 ± .9%), but the plateau phase was short and inconstant. All subsequent experiments were performed at 22°C.
When labeled angiotensin II was incubated with a broad range of platelet concentrations (5 X 10 4 to 2.0 X 10 6 cells/ju.1), we found a direct, significant relationship between binding and cell number (Fig. 2) . In each of nine experiments, the correlation coefficient relating these two variables was 0.96 or greater. Nonspecific binding also correlated with cell number although less consistently than did specific binding, and, at cell concentrations greater than 1 X 10 6 per jul, the increase in non-specific binding was disproportionately steepened. Consequently, in subsequent experiments, we used platelet concentrations between 6 and 8 X 10 5 cells per (il, giving specific binding in the 0.8-10% range.
Effect of Contaminating Red and White Blood Cells
When we examined the contaminating red and white blood cells contained in the platelet suspensions in six subjects, we found that these cells amounted to 1% of the total cell number (Table 1) . When we assessed binding of angiotensin II to these contaminants, 0.09 ± 0.02% of 125 I-angiotensin II bound nonspecifically in both the red cell and mononuclear leukocyte suspensions, but there was no detectable specific binding to either cell type. The non-specific binding in platelet suspensions was 0.48 ± .04%. These data suggest that the contaminating cells in the platelet preparations do not contribute to the specific binding observed, but may account for approximately 35% of the non-specific binding.
Non-competitive and Competitive Estimates of Affinity
Using increasing concentrations of 125 I-angiotensin II, the mass of specifically bound hormone increased in a dose-related fashion and plateaued at a concentration of 1 nM angiotensin II, indicating that the binding site was saturable (Fig. 3) . Non-specific bind- ing represented a constant percentage of hormone incubated over a broad range of hormone concentrations (0.05-2.5 n\i). Estimating the affinity of the receptors from direct analysis of the binding curve (i.e., ligand concentration at 50% receptor occupancy), the K D was 2.4 X 10" 10 M. The K D by Scatchard analysis of these data was 2.3 X 10~1 0 M. Unlabeled [Ile 5 ]angiotensin II competed with 125 Iangiotensin II in a dose-related fashion (Fig. 4) . Significant displacement of label was noted at concentrations of unlabeled hormone as low as 6 X 10~u M and 10" 9 M concentrations displaced 85% of the label. The KD estimated from these competition curves was 3.1 X 10" 10 M. The Scatchard plots were linear in most cases, but occasionally they were concave upward, suggesting a second, low affinity, "non-specific" site in some subjects. The KD of the saturable binding site by Scatchard analysis was 2.4 ± 0.3 X KT 10 M. Thus, there was good agreement in the affinities of the platelet receptor as calculated by Scatchard and displacement analyses.
Ligand Specificity
To determine the ligand specificity of this receptor, competition curves were prepared using several angiotensin peptides as the unlabeled hormone (Fig. 5) 
Effect of Dietary Sodium
Urinary electrolyte excretion indicated appropriate metabolic balance on both 10 and 200 mEq sodium diets (11 ± 3 vs. 190 ± 14 mEq Na/day). The supine PRA (4.4 ± 0.7 vs. 1.5 ± 0.5 ng/ml per hr) and plasma angiotensin II levels (49 ± 5 vs. 29 ± 3 pg/ml) were also consistent with the dietary sodium intakes. In any given subject, the platelet concentrations used in the binding assay were adjusted to be equivalent on both diets (6.0 ± 0.1 X 10 5 cells/fil on low salt and 6.1 ± 0.1 X 10 5 cells/jul on high salt). The binding of tracer amounts of angiotensin to platelets increased on the high salt intake compared to low salt. The mean specific binding of 30 pM 125 I-angiotensin II for the group was 1.76 ± 74% on the 10 mEq Na diet and 3.94 ± 1.23% on the 200 mEq Na diet (P < 0.001). Non-specific binding was the same on both diets (0.80 ± .06% on low salt vs. 0.77 ± 0.1% on high salt). Scatchard analysis of these data showed that the change in binding was related to an increase in receptor capacity with no significant change in affinity (Fig.  6) . The mean receptor capacity of the high affinity binding site was 4.9 ± 2.4 fmol/10 9 cells on the 10 mEq sodium diet and increased to 8.8 ± 3 . 7 fmol/10 9 cells on the 200 mEq diet (Fig. 7) . This increase in receptor capacity was observed in eight of nine subjects studied (P < 0.01). The affinity of the receptor was slightly higher on the high salt intake (KD = 1.8 ± 0.2 X 10" 10 M on high salt vs. 2.6 ± 0.4 X 10~1 0 M on low salt diet), but the difference did not achieve statistical significance (0.10 > P > 0.05). 
Discussion
Our understanding of the interaction between angiotensin II and its receptor site has improved rapidly in recent years, in parallel with improvements in receptor methodology. Receptor studies have clarified our understanding of the affinity and analogue specificity of the angiotensin receptor and have demonstrated that dietary sodium or Vol. 51, No. 3, September 1982 potassium intake may modify angiotensin receptor binding Devynck et al., 1978; Douglas, 1980; Gunther et al., 1980) . These studies provide a probable mechanism explaining the regulatory effects of dietary electrolytes on tissue responses to angiotensin II seen in earlier pharmacological studies (Laragh et al., 1980; Blair-West et al., 1970; Dluhy et al., 1972; Oelkers et al., 1974; Hollenberg et al., 1974) . Unfortunately, our understanding of the angiotensin receptor is based almost solely on animal studies. Studies in humans necessarily have been hampered by the inaccessibility of human target tissues. Thus, our knowledge of the human angiotensin receptor is based on indirect, pharmacological evidence: measurement of responses to the administration of angiotensin, angiotensin antagonists, and inhibitors of angiotensin-converting enzyme. Despite their limitations, these indirect methods have provided increasing evidence that tissue responsiveness to angiotensin II is altered in several disease states. In various studies, the adrenal, vascular, and/or renovascular responses have been found to be altered in essential hypertension, "low-renin" hypertension, and primary aldosteronism (Peart and Brown, 1961; Kaplan and Silah, 1964; Kisch et al., 1976; Moore et al., 1977; . These studies suggest the possibility of an altered angiotensin receptor in these conditions. The goal of our study, then, was to determine whether human blood cells might possess angiotensin receptors, affording us an opportunity for a more direct assessment of these receptors in man.
Circulation Research/
Our results indicate that human platelets possess specific, saturable binding sites for angiotensin II. The fact that preparations of red blood cells and mononuclear leukocytes displayed no specific binding at the concentrations tested confirms the fact that platelets were the site of the observed binding. [An earlier report had described the presence of angiotensin binding to human mononuclear leukocytes (Shimada and Yazaki, 1978 ), but we were unable to duplicate those findings.] We used 125 I-angiotensin II as our radiolabeled Iigand rather than the tritiated peptide because of the higher specific activity of the iodinated compound. The fact that receptor affinity was identical for both 125 I-angiotensin II and the native hormone (as evidence in the 125 I-angiotensin II saturation curve vs. competitive displacement studies) suggests that iodination of the hormone does not alter its binding to the platelet receptor site and thus justifies its use as a radiolabeled tracer in our subsequent studies. In this regard, the platelet receptor resembles the angiotensin receptors on animal target tissues which also bind iodinated and native angiotensin equally (Glossmann et al., 1974; Gunther et al., 1980a) .
The affinity of the platelet receptor (KD = 3 X 10" 10 M) also compared favorably with the affinities reported for animal adrenal (0.9-5 X 10~1 0 M) and vascular smooth muscle (5.6-9 X 10~1 0 ) (Gunther et al., 1980a) .
In addition, the ligand specificity of the platelet receptor for angiotensin and related peptides resembled that described for the receptors on classical animal target tissues . Of particular interest, the affinity was equal for angiotensin II and angiotensin III. This seems to disagree with the affinities expected from pharmacological studies: during angiotensin II and III infusions in man, the heptapeptide evokes only 15-30% of the pressor and steroidogenic effects of angiotensin II (Carey et al., 1978) . Utilizing receptor methodology, however, several groups have demonstrated similar affinities for these two peptides in adrenal and smooth muscle receptors in dogs, rabbits, and cattle (Capponi and Catt, 1979; Simpson et al., 1980; Gregory and Aguilera, 1981) . In addition, recent evidence has indicated that the different responses to infusion of these peptides may be related to differences in their degradation rates (Gregory and .
Our results also indicated that dietary sodium intake influenced platelet angiotensin binding. Sodium loading significantly increased the number of receptors without significantly changing receptor affinity. This pattern is similar to that observed in smooth muscle (both uterine and vascular) and brain angiotensin receptors from animal studies (Devynck et al., 1978; Gunther et al., 1980b; Mann et al., 1980) where sodium loading also increases receptor capacity. Conversely, high sodium intake reduces the number of adrenal angiotensin II receptors in animal studies Devynck et al., 1978; . Thus, from the viewpoint of receptor regulation, the platelet appears more akin to animal smooth muscle or brain.
The concentration of angiotensin receptors on platelets deserves additional comment. On the 200 mEq sodium intake, the level of high affinity binding observed is equivalent to approximately 10 receptor sites per cell. It is possible to compare the density of the angiotensin receptors on platelets to that on other angiotensin target tissues if one corrects for differences in cell size by relating the number of binding sites to the mass of cell membrane protein. Assuming 1 mg of platelet membrane protein per 10 9 cells [a value established in our lab as well as in the literature (Alexander et al., 1978) ], the platelet, with 10 fmol angiotensin bound/mg protein, has 20% of the receptor density reported in uterine smooth muscle (45 fmol/mg) and vascular smooth muscle (57 fmol/mg) Gunther et al., 1980b) . All these tissues exhibit considerably less receptor density than the adrenal glomerulosa cell (> 1000 fmol/mg) .
Whether the relatively low angiotensin receptor density observed in platelets would be sufficient to evoke some cellular response remains to be established. Such a role for angiotensin has been suggested by Poplowski (1971) who found that angiotensin II added to platelet suspensions enhanced the aggregation response to epinephrine. Further work is needed to confirm Poplowski's results. However, even in the absence of a definite function for angiotensin II in the platelet, the presence of angiotensin receptors on platelets provides promising opportunities for further study. The platelet, bearing receptors with affinity, ligand specificity, and dynamic regulation by sodium intake, similar to angiotensin receptors on "classical" target tissues, may provide the first readily accessible human tissue for a detailed study of angiotensin IIreceptor interaction in normal and hypertensive man.
